成人免费xx,国产又黄又湿又刺激不卡网站,成人性视频app菠萝网站,色天天天天

  2. JAK/STAT Signaling Stem Cell/Wnt Anti-infection
  3. STAT Parasite Antibiotic
  4. Niclosamide

Niclosamide  (Synonyms: 氯硝柳胺; BAY2353)

目錄號: HY-B0497 純度: 99.90%
COA 產(chǎn)品使用指南

Niclosamide (BAY2353) 是一種具有口服活性的用于寄生蟲感染研究的抗蠕蟲化合物。Niclosamide 是 STAT3 抑制劑，在 HeLa 細(xì)胞中的 IC50 為 0.25 μM。Niclosamide 具有抗癌的生物活性，并能抑制 Vero E6 細(xì)胞的 DNA 復(fù)制。

MCE 的所有產(chǎn)品僅用作科學(xué)研究或藥證申報(bào)，我們不為任何個(gè)人用途提供產(chǎn)品和服務(wù)

Niclosamide Chemical Structure

Niclosamide Chemical Structure

CAS No. : 50-65-7

1.  客戶無需承擔(dān)相應(yīng)的運(yùn)輸費(fèi)用。

2.  同一機(jī)構(gòu)（單位）同一產(chǎn)品試用裝僅限申領(lǐng)一次，同一機(jī)構(gòu)（單位）一年內(nèi)

     可免費(fèi)申領(lǐng)三個(gè)不同產(chǎn)品的試用裝。

3.  試用裝只面向終端客戶。

規(guī)格 價(jià)格 是否有貨 數(shù)量
10 mM * 1 mL in DMSO ￥550
In-stock
500 mg ￥400
In-stock
5 g ￥500
In-stock
10 g ￥800
In-stock
50 g   詢價(jià)  

* Please select Quantity before adding items.

Customer Review

Other Forms of Niclosamide:

    Niclosamide purchased from MCE. Usage Cited in: Biomed Pharmacother. 2023 May.

    Niclosamide (NIC) significantly suppresses the colony formation ability, and reduces the numbers, as well as diameters, of colonies formed in AN3CA, Hec1B, and Ishikawa cells.

    Niclosamide purchased from MCE. Usage Cited in: Biomed Pharmacother. 2023 May.

    Niclosamide (NIC; 1 μM) reduces number of cells that invaded across the trans-well chamber in Hec1B and Ishikawa endometrial cancer cell lines, suggesting NIC-mediated inhibition of invasive property of endometrial cancer cells.

    Niclosamide purchased from MCE. Usage Cited in: Biomed Pharmacother. 2023 May.

    Niclosamide (NIC; 0-8 μM; 24, 48, 72 h) significantly inhibits the metabolic viability of AN3CA, Hec1B, and Ishikawa cells both in a dose-dependent and a time-dependent manner, with the half maximal inhibitory concentration of < 1 μM at 72 h.

    Niclosamide purchased from MCE. Usage Cited in: Biomed Pharmacother. 2023 May.

    Niclosamide (NIC; 5?μM; 24?h) significantly reduces cyclin D1 and vimentin protein expression in human endometrial cancer cells.

    • 生物活性

    • 純度 & 產(chǎn)品資料

    • 參考文獻(xiàn)

    生物活性

    Niclosamide (BAY2353) is an orally active antihelminthic agent used in parasitic infection research[1]. Niclosamide is a STAT3 inhibitor with an IC50 of 0.25 μM in HeLa cells[4]. Niclosamide has biological activities against cancer, inhibits DNA replication in Vero E6 cells[2][3][5].

    IC50 & Target

    STAT3

    0.25 μM (IC50, in HeLa cells)

    細(xì)胞效力
    (Cellular Effect)
    Cell Line Type Value Description References
    A-431 IC50
    8.8 μM
    Compound: 5
    Antiproliferative activity against human A431 cells after 72 hrs by MTT assay
    Antiproliferative activity against human A431 cells after 72 hrs by MTT assay
    		[PMID: 24900231]
    A549 IC50
    0.4 μM
    Compound: Niclosamide
    Antiproliferative activity against human A549 cells after 120 hrs by MTT assay
    Antiproliferative activity against human A549 cells after 120 hrs by MTT assay
    		[PMID: 16680159]
    A549 CC50
    22.9 μM
    Compound: 6
    Cytotoxicity against human A549 cells assessed as reduction in cell viability after 48 hrs by alamar blue assay
    Cytotoxicity against human A549 cells assessed as reduction in cell viability after 48 hrs by alamar blue assay
    		[PMID: 32045239]
    A549 CC50
    22.9 μM
    Compound: 1
    Cytotoxicity against human A549 cells assessed as reduction in cell viability incubated for 48 hrs by alamarBlue assay
    Cytotoxicity against human A549 cells assessed as reduction in cell viability incubated for 48 hrs by alamarBlue assay
    		[PMID: 33112138]
    A549 IC50
    3 μM
    Compound: 5
    Antiproliferative activity against human A549 cells after 72 hrs by MTT assay
    Antiproliferative activity against human A549 cells after 72 hrs by MTT assay
    		[PMID: 24900231]
    ASPC1 IC50
    1.47 μM
    Compound: 1
    Cytotoxicity against human AsPC1 cells after 72 hrs by MTS assay
    Cytotoxicity against human AsPC1 cells after 72 hrs by MTS assay
    		[PMID: 23459613]
    ASPC1 IC50
    1.47 μM
    Compound: Niclosamide
    CYtotoxicity against human AsPC1 cells by MTS assay
    CYtotoxicity against human AsPC1 cells by MTS assay
    		[PMID: 23416191]
    BHK-21 CC50
    > 20 μM
    Compound: 104
    Cytotoxicity against BHK21 cells assessed as reduction in cell viability after 16 hrs by CCK-8 assay
    Cytotoxicity against BHK21 cells assessed as reduction in cell viability after 16 hrs by CCK-8 assay
    		[PMID: 28689975]
    Bone marrow cell IC50
    > 10 μM
    Compound: 89
    Cytotoxicity against human bone marrow cells incubated for 3 days by CellTiter-Glo luminescent assay
    Cytotoxicity against human bone marrow cells incubated for 3 days by CellTiter-Glo luminescent assay
    		[PMID: 31253529]
    Cancer cell lines IC50
    0.13 μM
    Compound: 1
    Cytotoxicity against human breast cancer cells assessed as growth inhibition after 72 hrs by Cell Titer Glo Assay
    Cytotoxicity against human breast cancer cells assessed as growth inhibition after 72 hrs by Cell Titer Glo Assay
    		[PMID: 26272032]
    Cancer cell lines IC50
    0.13 μM
    Compound: 1
    Cytotoxicity against human colon cancer cells assessed as growth inhibition after 72 hrs by Cell Titer Glo Assay
    Cytotoxicity against human colon cancer cells assessed as growth inhibition after 72 hrs by Cell Titer Glo Assay
    		[PMID: 26272032]
    Cancer cell lines IC50
    0.13 μM
    Compound: 1
    Cytotoxicity against human lung cancer cells assessed as growth inhibition after 72 hrs by Cell Titer Glo Assay
    Cytotoxicity against human lung cancer cells assessed as growth inhibition after 72 hrs by Cell Titer Glo Assay
    		[PMID: 26272032]
    Cancer cell lines IC50
    0.13 μM
    Compound: 1
    Cytotoxicity against human prostate cancer cells assessed as growth inhibition after 72 hrs by Cell Titer Glo Assay
    Cytotoxicity against human prostate cancer cells assessed as growth inhibition after 72 hrs by Cell Titer Glo Assay
    		[PMID: 26272032]
    Cancer cell lines IC50
    0.13 μM
    Compound: 1
    Cytotoxicity against human ovarian cancer cells assessed as growth inhibition after 72 hrs by Cell Titer Glo Assay
    Cytotoxicity against human ovarian cancer cells assessed as growth inhibition after 72 hrs by Cell Titer Glo Assay
    		[PMID: 26272032]
    Cancer cell lines IC50
    0.13 μM
    Compound: 1
    Cytotoxicity against human blood cancer cells assessed as growth inhibition after 72 hrs by Cell Titer Glo Assay
    Cytotoxicity against human blood cancer cells assessed as growth inhibition after 72 hrs by Cell Titer Glo Assay
    		[PMID: 26272032]
    Cancer cell lines IC50
    0.13 μM
    Compound: 1
    Cytotoxicity against human pancreatic cancer cells assessed as growth inhibition after 72 hrs by Cell Titer Glo Assay
    Cytotoxicity against human pancreatic cancer cells assessed as growth inhibition after 72 hrs by Cell Titer Glo Assay
    		[PMID: 26272032]
    CWR22R IC50
    1.61 μM
    Compound: 1
    Antiproliferative activity against human AR-positive 22Rv1 cells assessed as cell growth inhibition incubated for 3 days by WST-1 assay
    Antiproliferative activity against human AR-positive 22Rv1 cells assessed as cell growth inhibition incubated for 3 days by WST-1 assay
    		[PMID: 35772635]
    DLD-1 IC50
    2.39 μM
    Compound: Niclosamide
    Antiproliferative activity against human DLD1 cells after 72 hrs by colorimetric MTS assay
    Antiproliferative activity against human DLD1 cells after 72 hrs by colorimetric MTS assay
    		[PMID: 30274939]
    DU-145 IC50
    0.7 μM
    Compound: 5
    Antiproliferative activity against human DU145 cells after 72 hrs by MTT assay
    Antiproliferative activity against human DU145 cells after 72 hrs by MTT assay
    		[PMID: 24900231]
    DU-145 IC50
    0.7 μM
    Compound: 5
    Growth inhibition of human DU145 cells assessed as inhibition of colony formation after 11 to 12 days by crystal violet staining based microscopic analysis
    Growth inhibition of human DU145 cells assessed as inhibition of colony formation after 11 to 12 days by crystal violet staining based microscopic analysis
    		[PMID: 24900231]
    DU-145 IC50
    3.65 μM
    Compound: 1
    Antiproliferative activity against human AR-negative DU-145 cells assessed as cell growth inhibition incubated for 3 days by WST-1 assay
    Antiproliferative activity against human AR-negative DU-145 cells assessed as cell growth inhibition incubated for 3 days by WST-1 assay
    		[PMID: 35772635]
    HCT-116 EC50
    0.056 μM
    Compound: 1
    Effect on ATP homeostasis in human HCT116 cells assessed as reduction in ATP level after 3 hrs in absence of glucose by ATP bioluminescent assay
    Effect on ATP homeostasis in human HCT116 cells assessed as reduction in ATP level after 3 hrs in absence of glucose by ATP bioluminescent assay
    		[PMID: 28233680]
    HCT-116 IC50
    0.25 μM
    Compound: 1
    Effect on ATP homeostasis in human HCT116 cells assessed as reduction in ATP level after 3 hrs in absence of glucose by ATP bioluminescent assay
    Effect on ATP homeostasis in human HCT116 cells assessed as reduction in ATP level after 3 hrs in absence of glucose by ATP bioluminescent assay
    		[PMID: 28233680]
    HCT-116 IC50
    0.41 μM
    Compound: Niclosamide
    Antiproliferative activity against human HCT116 cells after 72 hrs by colorimetric MTS assay
    Antiproliferative activity against human HCT116 cells after 72 hrs by colorimetric MTS assay
    		[PMID: 30274939]
    HCT-116 IC50
    0.45 μM
    Compound: 1
    Cytotoxicity against human HCT116 cells assessed as growth inhibition after 72 hrs by MTS assay
    Cytotoxicity against human HCT116 cells assessed as growth inhibition after 72 hrs by MTS assay
    		[PMID: 26272032]
    HCT-116 IC50
    0.45 μM
    Compound: Niclosamide
    Antiproliferative activity against human HCT-116 cells assessed as inhibition of cell viability after 48 hrs by MTT assay
    Antiproliferative activity against human HCT-116 cells assessed as inhibition of cell viability after 48 hrs by MTT assay
    		[PMID: 33774344]
    HEK293 IC50
    0.34 μM
    Compound: 1
    Inhibition of Wnt3A-stimulated Wnt/beta-catenin pathway in HEK293 cells transfected with p8xTOPFlash, Renilla luciferase plasmid pRL-TK and pLKO.1 after 8 hrs by Dual topflash luciferase reporter gene assay
    Inhibition of Wnt3A-stimulated Wnt/beta-catenin pathway in HEK293 cells transfected with p8xTOPFlash, Renilla luciferase plasmid pRL-TK and pLKO.1 after 8 hrs by Dual topflash luciferase reporter gene assay
    		[PMID: 30551901]
    HEK293 IC50
    0.34 μM
    Compound: 1
    Inhibition of Wnt/beta-catenin in HEK293 cells assessed as inhibition of Wnt3A-stimulated TOPFlash activity after 8 hrs
    Inhibition of Wnt/beta-catenin in HEK293 cells assessed as inhibition of Wnt3A-stimulated TOPFlash activity after 8 hrs
    		[PMID: 26272032]
    HEK293 IC50
    0.4 μM
    Compound: Niclosamide
    Inhibition of Wnt3A/beta-casein signaling in HEK293 cells after 8 hrs by TOPflash reporter assay
    Inhibition of Wnt3A/beta-casein signaling in HEK293 cells after 8 hrs by TOPflash reporter assay
    		[PMID: 23453073]
    HEK293 IC50
    1.53 μM
    Compound: 89
    Inhibition of KIX-RLucN fused CBP (unknown origin) binding to KID-RLucC fused CREB (unknown origin) transfected in human HEK293 cells preincubated with compound 30 mins before before forskolin addition and measured after 90 mins in presence of coelenteraz
    Inhibition of KIX-RLucN fused CBP (unknown origin) binding to KID-RLucC fused CREB (unknown origin) transfected in human HEK293 cells preincubated with compound 30 mins before before forskolin addition and measured after 90 mins in presence of coelenteraz
    		[PMID: 31253529]
    HeLa IC50
    0.25 μM
    Compound: 5
    Inhibition of STAT3 in human HeLa cells after 24 hrs by luciferase reporter gene assay
    Inhibition of STAT3 in human HeLa cells after 24 hrs by luciferase reporter gene assay
    		[PMID: 24900231]
    HeLa IC50
    1.4 μM
    Compound: 5
    Antiproliferative activity against human HeLa cells after 72 hrs by MTT assay
    Antiproliferative activity against human HeLa cells after 72 hrs by MTT assay
    		[PMID: 24900231]
    HepG2 2.2.15 CC50
    > 100 μM
    Compound: Niclosamide
    Cytotoxicity against human HepG2(2.2.15) cells after 24 hrs by neutral red dye uptake assay
    Cytotoxicity against human HepG2(2.2.15) cells after 24 hrs by neutral red dye uptake assay
    		[PMID: 21553812]
    HL-60 IC50
    0.3 μM
    Compound: 89
    Cytotoxicity against human HL60 cells incubated for 3 days by CellTiter-Glo luminescent assay
    Cytotoxicity against human HL60 cells incubated for 3 days by CellTiter-Glo luminescent assay
    		[PMID: 31253529]
    HT-29 IC50
    0.13 μM
    Compound: Niclosamide
    Antiproliferative activity against human HT-29 cells after 72 hrs by colorimetric MTS assay
    Antiproliferative activity against human HT-29 cells after 72 hrs by colorimetric MTS assay
    		[PMID: 30274939]
    HT-29 IC50
    7.2 μM
    Compound: 5
    Antiproliferative activity against human HT-29 cells after 72 hrs by MTT assay
    Antiproliferative activity against human HT-29 cells after 72 hrs by MTT assay
    		[PMID: 24900231]
    Jurkat IC50
    0.4 μM
    Compound: 89
    Cytotoxicity against human Jurkat cells incubated for 3 days by CellTiter-Glo luminescent assay
    Cytotoxicity against human Jurkat cells incubated for 3 days by CellTiter-Glo luminescent assay
    		[PMID: 31253529]
    KG-1 IC50
    0.36 μM
    Compound: 89
    Cytotoxicity against human KG1 cells incubated for 3 days by CellTiter-Glo luminescent assay
    Cytotoxicity against human KG1 cells incubated for 3 days by CellTiter-Glo luminescent assay
    		[PMID: 31253529]
    LN-229 IC50
    0.3 μM
    Compound: 77
    Antiproliferative activity against human LN229 cells after 5 days by AlamarBlue assay
    Antiproliferative activity against human LN229 cells after 5 days by AlamarBlue assay
    		[PMID: 30583248]
    LNCaP IC50
    0.8 μM
    Compound: 1
    Antiproliferative activity against human AR-positive LNCaP cells assessed as cell growth inhibition incubated for 3 days by WST-1 assay
    Antiproliferative activity against human AR-positive LNCaP cells assessed as cell growth inhibition incubated for 3 days by WST-1 assay
    		[PMID: 35772635]
    LoVo IC50
    0.7 μM
    Compound: Niclosamide
    Antiproliferative activity against human LoVo cells after 120 hrs by MTT assay
    Antiproliferative activity against human LoVo cells after 120 hrs by MTT assay
    		[PMID: 16680159]
    MCF7 IC50
    1.06 μM
    Compound: 1
    Cytotoxicity against human ER positive MCF7 cells after 72 hrs by MTS assay
    Cytotoxicity against human ER positive MCF7 cells after 72 hrs by MTS assay
    		[PMID: 23459613]
    MCF7 IC50
    1.06 μM
    Compound: Niclosamide
    CYtotoxicity against ER-positive human MCF7 cells by MTS assay
    CYtotoxicity against ER-positive human MCF7 cells by MTS assay
    		[PMID: 23416191]
    MCF7 IC50
    8.13 μM
    Compound: 1
    Antiproliferative activity against human MCF7 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay
    Antiproliferative activity against human MCF7 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay
    		[PMID: 35334447]
    MDA-MB-231 IC50
    0.625 μM
    Compound: 27
    Anticancer activity against human MDA-MB-231 cells assessed as cell growth inhibition incubated for 24 hrs by MTT assay
    Anticancer activity against human MDA-MB-231 cells assessed as cell growth inhibition incubated for 24 hrs by MTT assay
    		[PMID: 33650861]
    MDA-MB-231 IC50
    0.79 μM
    Compound: 1
    Cytotoxicity against human ER negative MDA-MB-231 cells after 72 hrs by MTS assay
    Cytotoxicity against human ER negative MDA-MB-231 cells after 72 hrs by MTS assay
    		[PMID: 23459613]
    MDA-MB-231 IC50
    0.79 μM
    Compound: Niclosamide
    CYtotoxicity against ER-negative human MDA-MB-231 cells by MTS assay
    CYtotoxicity against ER-negative human MDA-MB-231 cells by MTS assay
    		[PMID: 23416191]
    MDA-MB-231 IC50
    0.8 μM
    Compound: Niclosamide
    Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell viability after 48 hrs by MTT assay
    Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell viability after 48 hrs by MTT assay
    		[PMID: 33774344]
    MDA-MB-231 IC50
    1.78 μM
    Compound: 1
    Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay
    Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay
    		[PMID: 35334447]
    MIA PaCa-2 IC50
    1.1 μM
    Compound: Niclosamide
    Antiproliferative activity against human MIAPaCa2cells after 120 hrs by MTT assay
    Antiproliferative activity against human MIAPaCa2cells after 120 hrs by MTT assay
    		[PMID: 16680159]
    NALM-6 IC50
    0.62 μM
    Compound: 89
    Cytotoxicity against human NALM6 cells incubated for 3 days by CellTiter-Glo luminescent assay
    Cytotoxicity against human NALM6 cells incubated for 3 days by CellTiter-Glo luminescent assay
    		[PMID: 31253529]
    PANC-1 IC50
    1.73 μM
    Compound: 1
    Cytotoxicity against human PANC1 cells after 72 hrs by MTS assay
    Cytotoxicity against human PANC1 cells after 72 hrs by MTS assay
    		[PMID: 23459613]
    PANC-1 IC50
    1.73 μM
    Compound: Niclosamide
    CYtotoxicity against human PANC1 cells by MTS assay
    CYtotoxicity against human PANC1 cells by MTS assay
    		[PMID: 23416191]
    PC-3 IC50
    0.4 μM
    Compound: Niclosamide
    Antiproliferative activity against human PC3 cells after 120 hrs by MTT assay
    Antiproliferative activity against human PC3 cells after 120 hrs by MTT assay
    		[PMID: 16680159]
    PC-3 IC50
    1.92 μM
    Compound: 1
    Antiproliferative activity against human AR-negative PC-3 cells assessed as cell growth inhibition incubated for 3 days by WST-1 assay
    Antiproliferative activity against human AR-negative PC-3 cells assessed as cell growth inhibition incubated for 3 days by WST-1 assay
    		[PMID: 35772635]
    PC-3 IC50
    11.7 μM
    Compound: 5
    Antiproliferative activity against human PC3 cells after 72 hrs by MTT assay
    Antiproliferative activity against human PC3 cells after 72 hrs by MTT assay
    		[PMID: 24900231]
    SH-SY5Y IC50
    0.87 μM
    Compound: Niclosamide
    Anticancer activity against human SH-SY5Y cells assessed as reduction in cell viability incubated for 48 hrs by resazurin dye based fluorescence assay
    Anticancer activity against human SH-SY5Y cells assessed as reduction in cell viability incubated for 48 hrs by resazurin dye based fluorescence assay
    		[PMID: 36208544]
    SK-N-AS IC50
    2.33 μM
    Compound: Niclosamide
    Anticancer activity against human SK-N-AS cells assessed as reduction in cell viability incubated for 48 hrs by resazurin dye based fluorescence assay
    Anticancer activity against human SK-N-AS cells assessed as reduction in cell viability incubated for 48 hrs by resazurin dye based fluorescence assay
    		[PMID: 36208544]
    SW480 IC50
    0.98 μM
    Compound: Niclosamide
    Antiproliferative activity against human SW480 cells after 72 hrs by colorimetric MTS assay
    Antiproliferative activity against human SW480 cells after 72 hrs by colorimetric MTS assay
    		[PMID: 30274939]
    SW480 IC50
    1 μM
    Compound: 93
    Anticancer activity against human SW480 cells assessed as reduction in cell viability incubated for 12 to 24 hrs by MTS assay
    Anticancer activity against human SW480 cells assessed as reduction in cell viability incubated for 12 to 24 hrs by MTS assay
    		[PMID: 33445154]
    SW948 IC50
    0.11 μM
    Compound: Niclosamide
    Antiproliferative activity against human SW948 cells after 72 hrs by colorimetric MTS assay
    Antiproliferative activity against human SW948 cells after 72 hrs by colorimetric MTS assay
    		[PMID: 30274939]
    T98G IC50
    0.3 μM
    Compound: 77
    Antiproliferative activity against human T98G cells after 5 days by AlamarBlue assay
    Antiproliferative activity against human T98G cells after 5 days by AlamarBlue assay
    		[PMID: 30583248]
    U138-MG IC50
    0.3 μM
    Compound: 77
    Antiproliferative activity against human U138MG cells after 5 days by AlamarBlue assay
    Antiproliferative activity against human U138MG cells after 5 days by AlamarBlue assay
    		[PMID: 30583248]
    U2OS CC50
    > 20 μM
    Compound: 104
    Cytotoxicity against human U2OS cells assessed as reduction in cell viability after 16 hrs by CCK-8 assay
    Cytotoxicity against human U2OS cells assessed as reduction in cell viability after 16 hrs by CCK-8 assay
    		[PMID: 28689975]
    U-373MG ATCC IC50
    0.3 μM
    Compound: 77
    Antiproliferative activity against human U373 cells after 5 days by AlamarBlue assay
    Antiproliferative activity against human U373 cells after 5 days by AlamarBlue assay
    		[PMID: 30583248]
    U-87MG ATCC IC50
    0.3 μM
    Compound: 77
    Antiproliferative activity against human U87 cells after 5 days by AlamarBlue assay
    Antiproliferative activity against human U87 cells after 5 days by AlamarBlue assay
    		[PMID: 30583248]
    U-87MG ATCC IC50
    0.4 μM
    Compound: Niclosamide
    Antiproliferative activity against human U87MG cells after 120 hrs by MTT assay
    Antiproliferative activity against human U87MG cells after 120 hrs by MTT assay
    		[PMID: 16680159]
    Vero EC50
    < 0.1 μM
    Compound: 21
    Antiviral activity against SARS coronavirus in Vero E6 cells assessed as inhibition of viral replication by ELISA
    Antiviral activity against SARS coronavirus in Vero E6 cells assessed as inhibition of viral replication by ELISA
    		[PMID: 17663539]
    Vero CC50
    > 50 μM
    Compound: Niclosamide
    Cell viability measured by CellTiter-Glo assay in Vero cells at MOI 0.05 after 72hr
    Cell viability measured by CellTiter-Glo assay in Vero cells at MOI 0.05 after 72hr
    		10.1101/2020.03.20.999730
    Vero IC50
    0.28 μM
    Compound: Niclosamide
    Antiviral activity against SARS-CoV-2 (viral titer) measured by plaque assay in Vero cells at MOI 0.0125 after 24 hr
    Antiviral activity against SARS-CoV-2 (viral titer) measured by plaque assay in Vero cells at MOI 0.0125 after 24 hr
    		10.1101/2020.03.20.999730
    Vero CC50
    22.1 μM
    Compound: 21
    Cytotoxicity against Vero E6 cells by MTT assay
    Cytotoxicity against Vero E6 cells by MTT assay
    		[PMID: 17663539]
    Vero C1008 CC50
    > 35.53 μM
    Compound: Niclosamide
    Cytotoxicity against African green monkey Vero E6 cells assessed as reduction of cell viability measured after 48 hrs by CCK-8 assay
    Cytotoxicity against African green monkey Vero E6 cells assessed as reduction of cell viability measured after 48 hrs by CCK-8 assay
    		[PMID: 32563814]
    Vero C1008 CC50
    1.03 μM
    Compound: 1
    Cytotoxicity against African Green monkey Vero E6 cells assessed as reduction in cell viability measured after 48 hrs by MTT assay
    Cytotoxicity against African Green monkey Vero E6 cells assessed as reduction in cell viability measured after 48 hrs by MTT assay
    		[PMID: 35344901]
    Vero C1008 CC50
    100 μM
    Compound: 1
    Cytotoxicity against African green monkey Vero E6 cells assessed as reduction in cell viability preincubated for 2 hrs followed by SARS-CoV-2 addition measured after 24 hrs by CPE assay
    Cytotoxicity against African green monkey Vero E6 cells assessed as reduction in cell viability preincubated for 2 hrs followed by SARS-CoV-2 addition measured after 24 hrs by CPE assay
    		[PMID: 35344901]
    體外研究
    (In Vitro)

    Niclosamide (0.6 nM-46 μM) 處理可抑制 BD140A、SW-13 和 NCI-H295R 細(xì)胞中的腎上腺皮質(zhì)癌細(xì)胞增殖[3]。
    Niclosamide (0.05-5 μM，24 h) 處理抑制 HeLa 細(xì)胞中 STAT3 介導(dǎo)的熒光素酶報(bào)告基因活性[4]。
    Niclosamide (10 μM) 處理抑制 Vero E6 細(xì)胞中的病毒復(fù)制[5]。

    MCE has not independently confirmed the accuracy of these methods. They are for reference only.

    Cell Viability Assay[3]

    Cell Line: BD140A, SW-13 and NCI-H295R cells
    Concentration: 0.6 nM-46 μM
    Incubation Time:
    Result: Inhibited cellular proliferation in adrenocortical carcinoma cell lines with the IC50 of 0.12 μM, 0.15 μM, and 0.53 μM in BD140A, SW-13, and NCI-H295R, respectively.

    Cell Viability Assay[4]

    Cell Line: Hela cells
    Concentration: 0.05-5 μM
    Incubation Time: 24 hours
    Result: Inhibited STAT3-mediated luciferase reporter activity with an IC50 of 0.25 μM.

    Cell Viability Assay[4]

    Cell Line: Vero E6 cells[5]
    Concentration: 10 μM
    Incubation Time: 2 days
    Result: Inhibited the synthesis of viral antigens of SARS-CoV in Vero E6 cells.
    體內(nèi)研究
    (In Vivo)

    Niclosamide (口服灌胃；100 mg/kg、200 mg/kg；每周一次；8 周) 處理抑制體內(nèi)腎上腺皮質(zhì)癌腫瘤生長[3]。

    MCE has not independently confirmed the accuracy of these methods. They are for reference only.

    Animal Model: Nu+/Nu+ mice injected with NCI-H295R cells[3]
    Dosage: 100 mg/kg, 200 mg/kg
    Administration: Oral gavage; 100 mg/kg, 200 mg/kg; once a week; 8 weeks
    Result: Showed a 60%-80% inhibition in tumor growth, as compared to the control group.
    Clinical Trial
    分子量

    327.12

    Formula

    C13H8Cl2N2O4
    CAS 號
    性狀

    固體

    顏色

    Light yellow to green yellow

    中文名稱

    氯硝柳胺；殺螺胺
    運(yùn)輸條件

    Room temperature in continental US; may vary elsewhere.
    儲存方式
    Powder -20°C 3 years
    4°C 2 years
    In solvent -80°C 1 year
    -20°C 6 months
    溶解性數(shù)據(jù)
    細(xì)胞實(shí)驗(yàn)： 

    DMF 中的溶解度 : 5 mg/mL (15.28 mM; 超聲助溶)

    DMSO 中的溶解度 : 4.55 mg/mL (13.91 mM; 超聲助溶; 吸濕的 DMSO 對產(chǎn)品的溶解度有顯著影響，請使用新開封的 DMSO)

    H2O 中的溶解度 : < 0.1 mg/mL (insoluble)

    配制儲備液
    濃度 溶劑體積 質(zhì)量 1 mg 5 mg 10 mg
    1 mM 3.0570 mL 15.2849 mL 30.5698 mL
    5 mM 0.6114 mL 3.0570 mL 6.1140 mL
    查看完整儲備液配制表

    * 請根據(jù)產(chǎn)品在不同溶劑中的溶解度選擇合適的溶劑配制儲備液；一旦配成溶液，請分裝保存，避免反復(fù)凍融造成的產(chǎn)品失效。
    儲備液的保存方式和期限：-80°C, 1 year; -20°C, 6 months。-80°C儲存時(shí)，請?jiān)?年內(nèi)使用， -20°C儲存時(shí)，請?jiān)?個(gè)月內(nèi)使用。

    • 摩爾計(jì)算器

    • 稀釋計(jì)算器

    Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

    質(zhì)量
    =
    濃度
    ×
    體積
    ×
    分子量 *

    Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

    This equation is commonly abbreviated as: C1V1 = C2V2

    濃度 (start)

    C1

    ×
    體積 (start)

    V1

    =
    濃度 (final)

    C2

    ×
    體積 (final)

    V2

    動物實(shí)驗(yàn)：

    請根據(jù)您的 實(shí)驗(yàn)動物和給藥方式 選擇適當(dāng)?shù)娜芙夥桨浮?

    以下溶解方案都請先按照 In Vitro 方式配制澄清的儲備液，再依次添加助溶劑：
    ——為保證實(shí)驗(yàn)結(jié)果的可靠性，澄清的儲備液可以根據(jù)儲存條件，適當(dāng)保存；體內(nèi)實(shí)驗(yàn)的工作液，建議您現(xiàn)用現(xiàn)配，當(dāng)天使用；
    以下溶劑前顯示的百分比是指該溶劑在您配制終溶液中的體積占比；如在配制過程中出現(xiàn)沉淀、析出現(xiàn)象，可以通過加熱和/或超聲的方式助溶

    • 方案 一

      請依序添加每種溶劑： 10% DMF    40% PEG300    5% Tween-80    45% Saline

      Solubility: 0.5 mg/mL (1.53 mM); 懸濁液; 超聲助溶

    以下溶解方案，請直接配制工作液。建議現(xiàn)用現(xiàn)配，在短期內(nèi)盡快用完。 以下溶劑前顯示的百分比是指該溶劑在您配制終溶液中的體積占比； 如在配制過程中出現(xiàn)沉淀、析出現(xiàn)象，可以通過加熱和/或超聲的方式助溶。

    • 方案 一

      請依序添加每種溶劑： 15% Cremophor EL    85% Saline

      Solubility: 20 mg/mL (61.14 mM); 懸濁液; 超聲助溶

    • 方案 二

      請依序添加每種溶劑： 5% Cremophor EL    95% (20% HP-β-CD in Saline)

      Solubility: 5 mg/mL (15.28 mM); 懸濁液; 超聲助溶

    動物溶解方案計(jì)算器
    請輸入動物實(shí)驗(yàn)的基本信息：

    給藥劑量

    mg/kg

    動物的平均體重

    g

    每只動物的給藥體積

    μL

    動物數(shù)量

    只
    由于實(shí)驗(yàn)過程有損耗，建議您多配一只動物的量
    請輸入您的動物體內(nèi)配方組成：
    %
    DMSO +
    % 
    +
    %
    Tween-80 +
    %
    Saline
    如果您的動物是免疫缺陷鼠或者體弱鼠，建議 DMSO 中的在最后工作液體系中的占比盡量不超過 2%。
    方案所需 助溶劑 包括：DMSO， ，均可在 MCE 網(wǎng)站選購。 ，Tween 80，均可在 MCE 網(wǎng)站選購。
    計(jì)算結(jié)果
    工作液所需濃度 : mg/mL
    儲備液配制方法 : mg 藥物溶于 μL  DMSO（母液濃度為 mg/mL）。
    您所需的儲備液濃度超過該產(chǎn)品的實(shí)測溶解度，以下方案僅供參考，如有需要，請與 MCE 中國技術(shù)支持聯(lián)系。
    動物實(shí)驗(yàn)體內(nèi)工作液的配制方法 : 取 μL DMSO 儲備液，加入 μL 。 μL ，混合均勻至澄清，再加 μL Tween 80，混合均勻至澄清，再加 μL 生理鹽水。
    連續(xù)給藥周期超過半月以上，請謹(jǐn)慎選擇該方案。
    請確保第一步儲備液溶解至澄清狀態(tài)，從左到右依次添加助溶劑。您可采用超聲加熱 （超聲清洗儀，建議頻次 20-40 kHz），渦旋吹打等方式輔助溶解。
    純度 & 產(chǎn)品資料

    純度: 99.90%

    參考文獻(xiàn)

    完整儲備液配制表

    * 請根據(jù)產(chǎn)品在不同溶劑中的溶解度選擇合適的溶劑配制儲備液；一旦配成溶液，請分裝保存，避免反復(fù)凍融造成的產(chǎn)品失效。
    儲備液的保存方式和期限：-80°C, 1 year; -20°C, 6 months。-80°C儲存時(shí)，請?jiān)?年內(nèi)使用， -20°C儲存時(shí)，請?jiān)?個(gè)月內(nèi)使用。

    可選溶劑 濃度 溶劑體積 質(zhì)量 1 mg 5 mg 10 mg 25 mg
    DMSO / DMF 1 mM 3.0570 mL 15.2849 mL 30.5698 mL 76.4246 mL
    5 mM 0.6114 mL 3.0570 mL 6.1140 mL 15.2849 mL
    10 mM 0.3057 mL 1.5285 mL 3.0570 mL 7.6425 mL
    DMF 15 mM 0.2038 mL 1.0190 mL 2.0380 mL 5.0950 mL
    Help & FAQs
    • Do most proteins show cross-species activity?

      Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

    您最近查看的產(chǎn)品:

    Your information is safe with us. * Required Fields.

       產(chǎn)品名稱：

    		  

    * 需求量：

    * 客戶姓名：

    		 

    * Email：

    * 電話：

    		 

    * 公司或機(jī)構(gòu)名稱：

       留言給我們：

    Bulk Inquiry

    Inquiry Information

    產(chǎn)品名稱：
    Niclosamide
    目錄號：
    HY-B0497
    需求量：